FGFR2 and breast cancer: All the results show that individuals with the A allele of FGFR2 rs2981578 presented a greater risk of overall toxicity for CET chemotherapy in breast cancer (adjusted OR = 2.37, 95% CI = 1.55—3.61, P < 0.0001).